Advertisement


Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response (German Language Version)

2017 Genitourinary Cancers Symposium

Advertisement

Roland Seiler, MD, of the University of British Columbia, discusses in German a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based neoadjuvant chemotherapy, and which patients show the most benefit. (Abstract 281)



Related Videos

Kidney Cancer

W. Marston Linehan, MD, on Renal Cell Carcinoma: Genetic Predisposition

W. Marston Linehan, MD, of the National Cancer Institute, discusses the genetic basis of the different types of kidney cancer, which provides the key to clinical management.

Bladder Cancer

Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response

Roland Seiler, MD, of the University of British Columbia, discusses a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based neoadjuvant chemotherapy, and which patients show the most benefit. (Abstract 281)

Bladder Cancer

Karim Chamie, MD, on Bladder Cancer: Optimizing Surgical and Medical Therapies

Karim Chamie, MD, of the University of California, Los Angeles, discusses induction and maintenance BCG therapy in non–muscle-invasive bladder cancer.

Prostate Cancer

L. Michael Glodé, MD, on Prostate Cancer: Results From SWOG S9921

L. Michael Glodé, MD, of the University of Colorado Cancer Center, discusses study findings on adjuvant androgen deprivation vs mitoxantrone plus prednisone plus ADT in high-risk prostate cancer patients following radical prostatectomy. (Abstract 2)

Prostate Cancer

Joshua M. Lang, MD, on Prostate Cancer: Best of the Journals

Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer than previously recognized–– and clinical trials with PARP inhibitors.

Advertisement

Advertisement




Advertisement